SLS Stock — SELLAS Life Sciences Group Inc.: Cash, EV, Pipeline

Share price

$11.49

Market cap

$2,320.4M

Cash

$138.3M

Enterprise value

$2,182.1M

Balance sheet

Cash	$138.3M
Debt	$0.0M
Net cash	$138.3M
Enterprise value	$2,182.1M
Basic shares	201.9M shares
Fully diluted shares	214.3M shares
Fully diluted market cap	$2,462.4M
Cash per share	$0.69

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading SLS daily closes…

Loading price history…

Upcoming catalysts

Expected	Drug	Phase	Indication	Mgmt guide
Feb 10 - Mar 24	SLS009	Phase 2	Hematologic Malignancies	—

Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.

Full readout calendar →

Pipeline assets

GPS

Phase 3 · Active Modality: peptide immunotherapy

Target WT1 (Wilms Tumor 1)

Partnerships Memorial Sloan Kettering Cancer Center (license); 3D Medicines (license for development and commercialization in mainland China, Hong Kong, Macau and Taiwan)

Indications

Acute myeloid leukemia (maintenance after second complete remission) (Phase 3)

Status note Lead candidate galinpepimut-S. Ongoing open-label randomized Phase 3 REGAL study of GPS monotherapy vs best available treatment in AML maintenance after CR2.

GPS Plus

Preclinical · Active Modality: peptide immunotherapy

Aliases heptavalent GPS

Target WT1 (Wilms Tumor 1)

Partnerships 3D Medicines (license for development and commercialization in mainland China, Hong Kong, Macau and Taiwan)

Status note Next-generation heptavalent immunotherapeutic at preclinical stage.

SLS009

Phase 2 · Active Modality: small molecule (oral)

Aliases tambiciclib

Target CDK9

Partnerships GenFleet Therapeutics (exclusive license; worldwide except mainland China, Hong Kong, Macau and Taiwan); IMPACT-AML (agreement to sponsor and conduct a clinical study evaluating SLS009)

Indications

Acute myeloid leukemia (Phase 2)

Status note Highly selective CDK9 inhibitor. Randomized Phase 2 trial in newly diagnosed first-line AML in combination with venetoclax and azacitidine ongoing, with enrollment begun in Q1 2026.

Per-asset detail extracted from the 10-Q filed 2026-08-11. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Galinpepimut-S
Lead indication	Acute Myeloid Leukemia
Lead phase	Phase 3
Active trials	2

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT04229979	Phase 3	Active, not recruiting	Sponsor	SLS	—	Acute Myeloid Leukemia	—
NCT04588922	Phase 2	Recruiting	Sponsor	SLS	—	Hematologic Malignancies	—

Sponsor-matched active trials from ClinicalTrials.gov (2 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for Sellas Life Sciences Group on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

SLS — SELLAS Life Sciences Group Inc.